SCHEMBL1240979

SCHEMBL1240979

N#Cc1cccc(C(NCc2cccc(C(F)(F)F)c2)C(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VNN1 O95497 3/20 0.44
KDM4E B2RXH2 1/20 0.41
KCNA5 P22460 5/20 0.41
CYP3A4 P08684 5/20 0.40
CLK4 Q9HAZ1 4/20 0.40
ALDH1A1 P00352 3/20 0.40
CYP1A2 P05177 3/20 0.40
CYP2C19 P33261 3/20 0.40
HSD17B10 Q99714 3/20 0.40
ALOX15 P16050 2/20 0.40
MAPK1 P28482 2/20 0.40
TSHR P16473 1/20 0.40
CYP3A5 P20815 2/20 0.39
KCNH2 Q12809 2/20 0.39
CLK1 P49759 1/20 0.39
DYRK1A Q13627 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39
SIGMAR1 Q99720 1/20 0.38
KIF11 P52732 1/20 0.38
CHEK1 O14757 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1242332 0.84 CYP19A1 (0.48) VNN1KDM4EKCNA5CYP3A4CLK4
SCHEMBL1240759 0.81 KCNA5 (0.46) KDM4EKCNA5CYP3A4CLK4ALDH1A1
SCHEMBL1243126 0.79 KCNA5 (0.40) VNN1KDM4EKCNA5CYP3A4CLK4
SCHEMBL1243076 0.78 KCNA5 (0.46) VNN1KCNA5CYP3A4CLK4ALDH1A1
SCHEMBL1243763 0.78 KCNA5 (0.43) VNN1KDM4EKCNA5CYP3A4CLK4
SCHEMBL1243158 0.77 CYP1A2 (0.41) VNN1KDM4EKCNA5CYP3A4CLK4
SCHEMBL1242943 0.77 VNN1 (0.40) VNN1KDM4EKCNA5CYP3A4CLK4
SCHEMBL1243167 0.77 TSHR (0.41) VNN1KCNA5CYP3A4CLK4ALDH1A1
SCHEMBL1243189 0.76 CYP19A1 (0.46) VNN1KCNA5CYP3A4CLK4ALDH1A1
SCHEMBL1242238 0.76 GRM5 (0.39) VNN1KCNA5CYP3A4CLK4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP claimed
JP-4719745-B2 2011-07-06 JP claimed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US claimed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US claimed
EP-1781635-B1 POTASSIUM CHANNEL INHIBITORS MERCK SHARP & DOHME (US) 2012-06-13 EP disclosed
US-7879839-B2 For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol MERCK SHARP & DOHME CORP. (US) 2011-02-01 US disclosed
US-20080090794-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME LLC 2008-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090794-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 VNN1 2972/4885KDM4E 364/4885KCNA5 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.